

SCRIP: 531686



**ADVIK LABORATORIES LIMITED**

Regd. Off. : 138, Roz Ka Meo Industrial Area, Sohna, Distt. Mewat Haryana - 122103

**STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED SEPTEMBER 30, 2014**

CIN : L74899HR1994PLC038300

Part-1							
Sno.	Particulars	Quarter ended 30.09.2014 (Unaudited)	Quarter ended 30.06.2014 (Unaudited)	Quarter ended 30.09.2013 (Unaudited)	Year to date figures for the current period ended 30.09.2014	Year to date figures for the previous period ended 30.09.2013	(Rs. in lacs) Previous year ended 31-03-14 (Audited)
1	a. Net Sales/ Income from operation (Net of excise duty)	443.38	319.89	340.86	763.27	1,071.79	2,908.07
	b. Other Operating Income	3.09	29.47	31.31	32.56	90.30	58.23
	<b>Total Income from Operations</b>	<b>446.47</b>	<b>349.36</b>	<b>372.17</b>	<b>795.83</b>	<b>1,162.09</b>	<b>2,966.30</b>
2	Expenditure						
	a. Cost of material consumed	408.43	325.50	298.22	733.93	1,066.65	2,392.91
	b. Purchase of Stock in Trade	-	-	-	-	-	-
	c. Changes in inventories of finished goods, work in progress & stock in trade	(64.38)	(53.18)	10.14	(117.56)	(43.43)	224.66
	d. Employee benefits expense	20.33	13.72	12.10	34.05	24.46	64.66
	e. Depreciation & amortisation expenses	19.90	14.50	13.50	34.40	25.50	68.45
	f. Other expense	31.57	17.07	9.55	48.64	19.30	64.68
	<b>Total Expenses</b>	<b>415.85</b>	<b>317.61</b>	<b>343.51</b>	<b>733.46</b>	<b>1,092.48</b>	<b>2,815.66</b>
3	Profit/(Loss) before other income, Finance Costs and Exceptional Items(1-2)	30.62	31.75	28.66	62.37	69.61	150.74
4	Other Income	5.63	-	0.05	5.63	0.36	61.42
5	<b>Profit/(Loss) from ordinary activities before finance costs &amp; exceptional items(3+4)</b>	<b>36.25</b>	<b>31.75</b>	<b>28.71</b>	<b>68.00</b>	<b>69.99</b>	<b>212.16</b>
6	Finance Costs	33.80	29.90	26.98	63.70	64.94	115.97
7	Profit/(Loss) from ordinary activities after finance costs but before exceptional items(5-6)	2.45	1.85	1.73	4.30	5.05	96.19
8	Exceptional Items	-	-	-	-	-	-
9	<b>Profit/(loss) from Ordinary Activities before tax (7+8)</b>	<b>2.45</b>	<b>1.85</b>	<b>1.73</b>	<b>4.30</b>	<b>5.05</b>	<b>96.19</b>
10	Tax Expenses including Deferred tax	0.74	0.55	0.53	1.29	1.56	49.62
11	<b>Net Profit/Loss from Ordinary Activities after Tax (9-10)</b>	<b>1.71</b>	<b>1.30</b>	<b>1.20</b>	<b>3.01</b>	<b>3.49</b>	<b>46.37</b>
12	Extra ordinary Items	-	-	-	-	-	-
13	<b>Net Profit/(Loss) for the period (11-12)</b>	<b>1.71</b>	<b>1.30</b>	<b>1.20</b>	<b>3.01</b>	<b>3.49</b>	<b>46.37</b>
14	Paid up Equity Share Capital (Rs. 10/- per share)	1,502.88	1,502.88	935.34	1,502.88	935.34	1,502.88
15	Reserve excluding revaluation reserves	-	-	-	-	-	234.85
16	Earning per share						
	a) Basic	0.012	0.010	0.013	0.021	0.037	0.412
	b) Diluted	0.010	0.010	0.013	0.017	0.037	0.368
Part - 2							
A.	Particulars of Shareholding						
1	Public Shareholdings						
	No. of Shares	10248129	10248129	6830429	10248129	6830429	10248129
	Percentage of above	68.19%	68.19%	73.03%	68.19%	73.03%	68.19%
2	Promoters & Promoter group						
	a) Pledged/Encumbered	Nil	Nil	Nil	Nil	Nil	Nil
	b) Non-Encumbered						
	- No. of Shares	4780621	4780621	2522971	4780621	2522971	4780621
	- Percentage of shares(as a % of total shareholding of promoter & promoter group)	100%	100%	100%	100%	100%	100%
	- Percentage of shares(as a % of total share capital of the Company)	31.81%	31.81%	26.97	31.81%	26.97	31.81%
B	Investor Complaints						
	Pending at the beginning of the Qtr.	Nil					
	Received during the Qtr.	1					
	Disposed of during the Qtr.	1					
	Remaining unresolved during the Qtr.	Nil					



Statement of Assets & Liabilities as on September 30, 2014

(Rs. In lacs)


Particulars	As at 30.09.14 (Unaudited)	As at 31.03.14 (Audited)
<b>A. EQUITY &amp; LIABILITIES</b>		
<b>1 Shareholder's Funds</b>		
(a) Share Capital	1,502.88	1,502.88
(b) Money received against Share warrants	270.24	270.24
(c) Reserve and Surplus	237.86	234.85
<b>Sub-total-Shareholder's funds</b>	<b>2,010.98</b>	<b>2,007.97</b>
<b>2 Non-Current Liabilities</b>		
(a) Long Term borrowings	459.31	299.32
(b) Deferred tax liabilities (Net)	122.59	122.59
(c) Other long term liabilities	-	-
(d) Long Term Provisions	12.12	12.12
<b>Sub-total-Non Current Liabilities</b>	<b>594.02</b>	<b>434.03</b>
<b>3 Current Liabilities</b>		
(a) Short term borrowings	400.55	404.67
(b) Trade payables	356.45	448.16
(c) Other current liabilities	93.26	168.76
(d) Short Term provisions	18.62	18.33
<b>Sub-total Current Liabilities</b>	<b>869.88</b>	<b>1,039.92</b>
<b>TOTAL EQUITY &amp; LIABILITIES</b>	<b>3,474.88</b>	<b>3,481.92</b>
<b>B. ASSETS</b>		
<b>1 Non Current Assets</b>		
(a) Fixed Assets	1,484.22	1,517.94
(b) Non Current Investments	92.30	92.30
<b>Sub-total-Non current assets</b>	<b>1,576.52</b>	<b>1,610.24</b>
<b>2 Current Assets</b>		
(a) Inventories	846.91	679.85
(b) Trade receivables	692.28	864.86
(c) Cash & cash equivalents	11.42	5.26
(d) Short term loan and advances	338.85	265.39
(e) Other current assets	8.90	56.32
<b>Sub-total Current Assets</b>	<b>1,898.36</b>	<b>1,871.68</b>
<b>TOTAL ASSETS</b>	<b>3,474.88</b>	<b>3,481.92</b>

Notes:

1. The above Financial Results were reviewed by the Audit Committee and taken on record by the Board of Directors in their meeting held on 14th November, 2014
2. The Company is operating only in the Pharmaceuticals Segment, hence Reporting as defined in AS-17 is not applicable.
3. Previous year/period figures have been regrouped/rearranged, wherever necessary to make them comparable with the current period

Place: New Delhi  
Date : 14.11.2014

For Advik Laboratories Limited

  
(Peeyush Kumar Aggarwal)  
Chairman

